Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 3/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27341113 | 0.89 | CES2 (0.33) | CES2CA12CA1CA9CA2 | |
| SCHEMBL20628161 | 0.88 | CA12 (0.37) | CES2CA12CA1CA9CA2 | |
| SCHEMBL22035307 | 0.86 | CES2 (0.32) | CES2CA12CA1CA9CA2 | |
| SCHEMBL24557245 | 0.85 | CA12 (0.35) | CES2CA12CA1CA9CA2 | |
| SCHEMBL24709510 | 0.84 | CA12 (0.34) | CES2CA12CA1CA9CA2 | |
| SCHEMBL22907293 | 0.84 | CES2 (0.31) | CES2CA12CA1CA9CA2 | |
| SCHEMBL21324002 | 0.84 | CES2 (0.31) | CES2CA12CA1CA9CA2 | |
| SCHEMBL23766685 | 0.82 | CA12 (0.37) | CES2CA12CA1CA9CA2 | |
| SCHEMBL27254735 | 0.78 | CA12 (0.44) | CES2CA12CA1CA9CA2 | |
| SCHEMBL25989963 | 0.78 | CA12 (0.44) | CES2CA12CA1CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144330-A1 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | CureVac SE (DE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022135993-A2 | PHARMACEUTICAL COMPOSITION COMPRISING LIPID-BASED CARRIERS ENCAPSULATING RNA FOR MULTIDOSE ADMINISTRATION | CUREVAC AG (DE) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021239880-A9 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021239880-A1 | NUCLEIC ACID BASED COMBINATION VACCINES | CUREVAC AG (DE) | 2021-12-02 | — | — | WO | disclosed |
| WO-2020254535-A1 | ROTAVIRUS MRNA VACCINE | CUREVAC AG (DE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2018078053-A1 | LIPID NANOPARTICLE MRNA VACCINES | CUREVAC AG (DE) | 2018-05-03 | — | — | WO | disclosed |